Biotechs like Chimeric, BCAL Diagnostics and Radiopharm were sold off by investors in 2022, and there's no guarantee of a bounce back, says SG Hiscock's Rory Hunter
Biotech investors believe the market has bottomed out, but any upwards swings are likely to be stock-specific rather than a broad-based boom.